Aduro Biotech helps launch new immunotherapy, vaccine effort

"MCB cancer immunologists are teaming up with colleagues working on infectious disease to create a new Immunotherapeutics and Vaccine Research Initiative, fueled by $7.5 million in funding from Aduro Biotech Inc., a Berkeley company that develops immunotherapies for cancer and other diseases."


Photo courtesy of Peg Skorpinski. Pictured: Stephen Isaacs, CEO of Aduro Biotech, at the launch of the IVRI on March 23.